Alnylam Pharmace. buy Evercore ISI
Start price
11.09.25
/
50%
€399.10
Target price
11.09.26
€440.26
Performance (%)
-29.22%
Price
15.04.26
€282.50
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -29.22%. This prediction currently runs until 11.09.26. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 0.749% | 0.749% |
| iShares Core DAX® | 0.444% | 3.030% |
| iShares Nasdaq 100 | 3.819% | 4.073% |
| iShares Nikkei 225® | 1.148% | 6.904% |
| iShares S&P 500 | 2.371% | 2.677% |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Evercore ISI from $280.00 to $515.05. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Evercore_ISI for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€221.10
25.06.24
25.06.24
€242.92
25.06.25
25.06.25
25.69%
26.06.25
26.06.25
